WO2023099932A1 - Cd31 mimetic coating for endovascular stent - Google Patents

Cd31 mimetic coating for endovascular stent Download PDF

Info

Publication number
WO2023099932A1
WO2023099932A1 PCT/IB2021/000860 IB2021000860W WO2023099932A1 WO 2023099932 A1 WO2023099932 A1 WO 2023099932A1 IB 2021000860 W IB2021000860 W IB 2021000860W WO 2023099932 A1 WO2023099932 A1 WO 2023099932A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
homophilic
trans
domain
intercellular interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2021/000860
Other languages
English (en)
French (fr)
Inventor
Giuseppina Caligiuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Université Sorbonne Paris Nord
Université Paris Cité
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Université Sorbonne Paris Nord
Université Paris Cité
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale, Université Sorbonne Paris Nord, Université Paris Cité filed Critical Institut National de la Santé et de la Recherche Médicale
Priority to PCT/IB2021/000860 priority Critical patent/WO2023099932A1/en
Priority to CA3241253A priority patent/CA3241253A1/en
Priority to KR1020247022289A priority patent/KR20240155852A/ko
Priority to AU2022402537A priority patent/AU2022402537B2/en
Priority to US18/715,588 priority patent/US20250281679A1/en
Priority to KR1020247022306A priority patent/KR20240155186A/ko
Priority to PCT/IB2022/000684 priority patent/WO2023099957A2/en
Priority to CN202280082480.3A priority patent/CN118843485A/zh
Priority to EP22830701.3A priority patent/EP4440644A2/en
Priority to JP2024532974A priority patent/JP2024542778A/ja
Priority to EP22829836.0A priority patent/EP4440643A2/en
Priority to PCT/EP2022/084241 priority patent/WO2023099748A2/en
Priority to CN202280082519.1A priority patent/CN118475376A/zh
Priority to US18/715,251 priority patent/US20250381324A1/en
Priority to JP2024532976A priority patent/JP2024542779A/ja
Priority to IL313268A priority patent/IL313268A/en
Publication of WO2023099932A1 publication Critical patent/WO2023099932A1/en
Priority to MX2024006730A priority patent/MX2024006730A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment

Definitions

  • the present invention finds application in the medical field and in particular to improve the integration and performance of implantable medical devices.
  • a “foreign body response” is caused by the injury of the tissue at the site of implantation and initiated by the contact of the non-biocompatible material with the blood.
  • the adherence and activation of platelets followed by the recruitment of inflammatory cells is followed by an aberrant wound healing sequence characterized by a chronic inflammation and the formation of granulomatous tissue.
  • the interruption of the endothelial barrier allows the activation of platelets, to seal off the damage, and infiltration of leukocytes to clear the debris and prepare the site for tissue regeneration.
  • the excessive platelet adhesion and aggregation can cause the obstruction of the blood flow (ischemia) whereas the proteases released by activated platelets and leukocytes can lead to the rupture of the vascular wall (hemorrhage).
  • One of such condition is triggered by the presence of heart valves and vascular devices, which are seen as foreign elements to the body.
  • CD31 is a transmembrane glycoprotein expressed constitutively and exclusively on platelets, leukocytes, and endothelial cells (EC). Under healthy conditions, the trans- homophilic CD3LCD31 interaction allows the recognition of the “self’ by endothelial cells, platelets, and leukocytes preventing their inappropriate activation.
  • the favorable issue of blood-contacting implantable devices can be achieved by treatments rendering their surface “biocompatible” to allow the rapid formation of a functional endothelial layer on them and ensuring a proper integration of the biomaterial.
  • CD31 The abundant expression of CD31 by the healthy endothelium exerts an essential role for the maintenance of the homeostasis in the circulation and vascularized tissues.
  • Cortese et al discloses that the immobilization of a CD31- mimetic peptide P8RI (kwpalfvr) reduces the blood element reaction, increases the adhesion of endothelial cells in vitro and enhances the integration of endovascular devices in vivo.
  • P8RI kwpalfvr
  • Diaz-Rodriguez et al discloses that the soluble peptide referred to as P8RI acts like a CD31 agonist; therefore, it has been studied the effect of CD31 -mimetic metal stent coating on the in vitro adherence of endothelial cells and blood elements and the in vivo endothelial strut coverage and foreign body response-driven neointimal growth.
  • CD31 is a type I transmembrane glycoprotein composed of 6 extracellular Ig-like domains, numbered starting from the membrane distal N-terminus, a short transmembrane fragment, and a cytoplasmic tail.
  • CD31 depends upon a trans-homophilic interaction between domains 1 and 2 of the molecules expressed by a cell and the same domains expressed by the interacting cell.
  • the trans-homophilic interaction of CD31 domains 1 and 2 drives the clusterisation of the molecules by lateral displacement and strong cis-homophilic interaction of the transmembrane and juxtamembrane extracellular sequence.
  • This cis-homophilic interaction occurs at sites of cell activation and is essential for allowing the regulatory function of CD31 because this protein is not able to autophosphorylate.
  • CD31 phosphorylation depends on the ability of the molecules to remain clustered close to activated tyrosine kinase receptors.
  • the amino acids included in the P8RI sequence are issued from the cis- homophilic juxta-membrane portion of CD31. P8RI co-clusters with this sequence and up-holds the regulatory signaling properties of truncated CD31 molecules in activated endothelial cells, platelets and leukocytes at site of inflammation or thrombosis.
  • the inventors of the present patent application have surprisingly found some peptides endowed with the property of mimicking the trans-homophilic (domain 1 and 2) CD31-CD31 intercellular interaction.
  • peptides having the property of mimicking the trans-homophilic CD31-CD31 domain 1 and 2 intercellular interaction.
  • said peptides may have three different general structures.
  • the medical use is for the prevention of complications associated with the implantation of medical devices to treat heart and vascular pathologies.
  • the medical use is for the treatment of heart vascular pathologies.
  • a coating comprising the disclosed biomimetic peptides.
  • a method for the preparation of the coating comprising the disclosed biomimetic peptides.
  • a method for the prevention or for the treatment or for the diagnosis of vascular pathologies comprising the use of the biomimetic peptides of the invention.
  • biomimetic peptides of the invention for the adhesion to the surface of a device.
  • biomimetic peptides of the invention for the adhesion to a vascular device.
  • biomimetic peptides of the invention for promoting the endothelialization of an arterial vessel, for preventing the neointimal growth and for the integration of a device in the target vessel.
  • biomimetic is to be intended as the mimicking of a natural effect.
  • the biomimetic peptides are endowed with the property of mimicking the natural effect of the endothelium, i.e. the layer of endothelial cells (ECs) coating the interior wall of the vessels and particular of arteries.
  • ECs endothelial cells
  • Said mimicking property can also be provided to a surface, which is covered with the peptides of the invention.
  • the peptides of the invention mimic the trans-homophilic CD31-CD31 domain 1 and 2 intercellular interaction.
  • biomimicking peptides of the invention are based on the following sequence IA:
  • biomimicking peptides of the invention are based on the following sequence IB:
  • biomimicking peptides of the invention are based on the following sequence IC:
  • the biomimicking peptides also include cyclic peptides; in particular, the cysteine comprising biomimicking peptides may be in the cyclic form through disulfide bond.
  • the biomimicking peptides may comprise linkers and/or spacer and/or a tail, optionally represented by an aminoacidic sequence; in particular, said sequence may be linked to a peptidic terminus or to one amino acid residue.
  • said aminoacidic sequence may be represented by the following sequence:
  • biomimicking peptides also include heteropeptides comprising two of the above described peptidic sequence.
  • the heteropeptides may comprise: a peptide having a sequence based on structure IA and a peptide having a sequence based on structure IB, or a peptide having a sequence based on structure IA and a peptide having a sequence based on structure IC.
  • the heteropeptides may comprise peptidic sequences linked through acetyl thioether linkage between amino acids of different sequences or between linkers and/or spacers.
  • the peptides of the invention are based on the following sequences: As per preferred aspect, the peptides of the invention are based on the following sequences:
  • peptides of the invention are based on the following structures:
  • peptides of the invention are based on the following structures:
  • heteropeptides of the invention are characterized by comprising the following peptides:
  • the biomimicking peptides of the invention may comprise any of the below modifications: a cysteine residue may be substituted by the corresponding homocysteine residue, an L-amino acid may be substituted by the corresponding D-amino acid.
  • the biomimicking peptides of the invention may comprise a spacer and/or a linker and/or a tail, selected from: and combinations thereof, such as for instance:
  • the above disclosed structures may comprise modifications at the C-terminus and/or at the N-terminus.
  • said modifications may comprise:
  • biomimicking sequences there are disclosed the following biomimicking sequences:
  • the biomimicking peptides of the invention comprise peptides having at least 95% identity of the above disclosed structure, preferably at least 97% and even more preferably at least 99%.
  • the medical use is for the prevention of vascular pathologies.
  • said pathologies are selected from the group comprising: heart valve pathology, atherosclerosis, thrombosis, ischemia, hemorrhage, restenosis, aneurysm.
  • the medical use is for the treatment of vascular pathologies.
  • a coating comprising the disclosed biomimetic peptides.
  • the coating is a mono-layered coating, while as per an alternative embodiment of the invention it is a multi-layer coating.
  • a method for the preparation of the coating comprising the disclosed biomimetic peptides.
  • the coating of a device or of a portion thereof can be obtained with dip-coating, by immersion of the portion to be coated within a coating bath.
  • the method is a three-step dip coating method comprising: a first step for a polydopamine coating, a second step for the grafting of a suitable linker, and a third step for the coating with the invention peptide.
  • devices comprising a portion coated with the biomimetic peptides or the coating of the invention.
  • Coating may comprise the whole surface of a device or of a part of a device.
  • the fully or partially coated devices may be in any suitable material, such as, for instance: metal or alloys: stainless steel, cobalt-chromium alloy, platinum-chromium alloy or nickel-titanium alloy; synthetic polymeric materials: Dacron®, Teflon®; clinical-grade biological tissues, such as pericardial sheets for heart valves bioprostheses.
  • metal or alloys stainless steel, cobalt-chromium alloy, platinum-chromium alloy or nickel-titanium alloy
  • synthetic polymeric materials Dacron®, Teflon®
  • clinical-grade biological tissues such as pericardial sheets for heart valves bioprostheses.
  • a method for the prevention or for the treatment of heart and vascular pathologies comprising the use of the biomimetic peptides of the invention.
  • said method for the prevention or for the treatment of heart and vascular pathologies comprises the use of a device fully or partially coated with the coating of the invention.
  • said pathologies are represented by: heart valve pathology, atherosclerosis, thrombosis, ischemia, hemorrhage, restenosis, aneurism.
  • biomimetic peptides of the invention for the adhesion to the surface of a device.
  • biomimetic peptides of the invention for the adhesion to vascular device.
  • biomimetic peptides of the invention for promoting the endothelialization of a vessel, for preventing the neointimal growth and for the integration of a device in the target vessel.
  • a target vessel is represented by an arterial vessel.
  • biomimetic peptides of the invention for improving the biocompatibility of a device.
  • biomimetic peptides of the invention for endowing the stented segment with recovered endothelial anti-inflammatory and anti-thrombotic properties.
  • biomimetic peptides of the invention for endowing the stented segment with improved adaptive remodelling allowing recovery of its functional properties.
  • present invention will be further disclosed in the following non-limitative examples.
  • Figures 1A and IB show the structure of the octa-peptide P8RI.
  • Figure 2 shows the strategy used to analyze the biocompatibility of nitinol disks interacting with human endothelial cells.
  • Figure 3 shows representative images and quantification of the F-actin staining of HAEC growing onto bare and coated disks.
  • Figure 4 shows representative images and quantification of the CD31 staining of HAEC growing onto bare and coated disks.
  • Figure 5 shows quantitative analysis of F-actin and CD31 expression on HAEC growing onto coated vs bare control nitinol disks.
  • Figure 6 shows the ratio between CD31 and F-actin expression.
  • Figures 7 to 17 show the structure of the preferred peptides of the invention.
  • Figure 18 shows the structure of the intermediate A.
  • Figure 19 shows the structure of the intermediate B.
  • Figure 20 shows the structure of the intermediate C.
  • Figure 21 shows the structures of linkers according to the present invention.
  • AA refers to amino acid
  • Boc refers to tert-butyloxycarbonyl
  • tBu refers to tertiary butyl
  • DCM dichloromethane
  • DIC refers to N,N'-diisopropylcarbodiimide
  • DIPEA refers to N, N-Diisopropiletylamine
  • DMF dimethylformamide
  • Fluorenyl refers to fluorenylmethyloxycarbonyl
  • HO At refers to l-hydroxy-7-azabenzotriazole
  • HPLC High Performance Liquid Chromatography
  • LCMS Liquid Chromatography/Mass Spectrometry
  • RP-HPLC refers to reversed-phase high performance liquid chromatography
  • MS refers to mass spectrometry
  • Oxyma refers to ethyl cyanohydroxyiminoacetate
  • Pbf refers to 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
  • TIPS refers to triisopropylsilane
  • TAA trifluoroacetic acid
  • Trt refers to trityl
  • the peptides were synthesized by standard Solid-phase Peptide Synthesis (SPPS) using Fmoc/t-Bu chemistry. DMF was used as the solvent. The following starting materials and methods were employed in the synthetic procedures described in the examples.
  • Fmoc-protected natural amino acids were purchased from Novabiochem, Iris Biotech, Bachem or Chem-Impex International. The following standard amino acids were used in the syntheses: Fmoc-L-Ala-OH, Fmoc-L-Arg(Pbf)-OH, Fmoc-L-Asn(Trt)-OH, Fmoc-L-Asp(OMpe)-OH, Fmoc-L-Gln(Trt)-OH, Fmoc-L-Glu(OtBu)-OH, Fmoc-L-Gly- OH, Fmoc-L-Ile-OH, Fmoc-L-Leu-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-L-Pro-OH, Fmoc- L-Ser(tBu)-OH, Fmoc-L-Thr(tBu)-OH, Fmoc-L-Tyr(t
  • amino acids were purchased from the same suppliers as above: Fmoc-K-(N3)OH; Fmoc-K(alloc)OH; Fmoc-c-OH, Fmoc-hC-OH, Fmoc-Ttds- COOH, Fmoc-NH-PEG4-COOH.
  • Mass analyzer Waters SQ Detector with electrospray ionization in positive ion detection mode
  • Mass analyzer Waters SQ Detector with electrospray ionization in positive ion detection mode
  • Mass analysis was performed on a Waters SQ Detector with electrospray ionization in positive ion detection mode and the scan range of the mass-to-charge ratio was 400-1800.
  • the synthesis of all the peptides was performed by standard Fmoc stepwise solid phase synthesis (SPPS) on a Liberty Blue microwave synthesizer (CEM corp.).
  • SPPS standard Fmoc stepwise solid phase synthesis
  • CEM corp. Liberty Blue microwave synthesizer
  • the assembly was performed using a Protide Rink-amide (4-(2’,4’-Dimethoxyphenyl-Fmoc- aminomethyl)-phenoxyacetamido-norleucylaminomethyl resin, CEM, 200 pmol, 100-200 Mesh; loading 0.2 mmol/g) on a 0.2 mmol scale, with DIC/Oxyma activation. DMF was used as the solvent.
  • the cleavage mixture was collected by filtration, the crude peptides were precipitated in methyl tert-butyl ether, centrifuged, the supernatant was removed, fresh diethyl ether was added to the peptides and re-centrifuged, twice; the crude peptides were then lyophilized.
  • Peptides were analyzed by analytical UPLC and verified by ESI+ mass spectrometry. Crude peptides were purified by a conventional preparative RP-HPLC purification on a preparative Waters 2489 HPLC system, (UV detection at wavelength 214 nm); the following solvents as eluents: acetonitrile + 0.1% TFA (mobile phase A) and water + 0.1% TFA (mobile phase B). Product containing fractions were collected and lyophilized to obtain the purified product as a TFA salt. Unless otherwise described the compounds were tested as TFA salt.
  • Seq ID 1 spans region His71-Ser87 of CD31 IgLl-A with an acetylated N- terminal D-Cysteine and a Cysteine at the C-terminal position of Ser87, with the two thiol groups engaged in a disulfide bond.
  • the purified peptide was solubilized at 1 mg/mL concentration in a mixture of acetonitrile/water 8/2: HC1 50 mM (10 eq) was added, and mixture stirred for 1 hour at room temperature. After lyophilization, the peptide was dissolved in acetonitrile/water 8/2 and freeze dried again. The peptide was analyzed by LC/MS (Method C). [M+3H] 3+ mass signal found under the peak with retention time 3.27 min revealed the peptide mass 1013.5 which is in line with the expected value of molecular weight 3036.37.
  • Seq ID 2 (PepSP745) spans the same region His71-Ser87 of CD31 IgLl-A, common with Seq ID 1 but it is a linear sequence with replacement of the two cysteine residues in seq ID1 in Serines.
  • the peptide was solubilized at 1 mg/mL concentration in a mixture of acetonitrile/water 8/2: HC1 50 mM (10 eq) was added, and mixture stirred for 1 hour at room temperature. After lyophilization, the peptide was dissolved in acetonitrile/water 8/2 and freeze dried again. The peptide was analyzed by LC/MS (Method C). [M+3H] 3+ mass signal found under the peak with retention time 2.85 min revealed the peptide mass 989.4 which is in line with the expected value of molecular weight 2964.22.
  • Seq ID 3 (PepSP765) spans the same region His71-Ser87 of CD31 IgLl-A and similar disulfide connectivity of seq ID 1 but with a solubilizing tail at the N-terminus of 3 lysine residues.
  • Seq ID 4 (PepSP1375) spans the same region Gln70-Lys89 of CD31 IgLl-A and a long linker of Ttds units (see Table 1)
  • Seq ID 5 (PepSP1374) spans the same region Gln70-Lys89 of CD31 IgLl-A of Seq ID 4 with mutations to homocysteines: Gln70hCys and Lys89hCys that results in a disulfide bond with a cyclic structure.
  • Seq ID 6 (PepSP1072) spans the region Tyrl07-Glul22 of CD31 IgLl-A.
  • the purified peptide was analyzed by LC/MS (Method A). [M+3H] 3+ mass signal found under the peak with retention time 2.97 min revealed the peptide mass 743.0 which is in line with the expected value of molecular weight 2226.54.
  • Seq ID 7 (PepSP1376) spans the region 106-124 where position 106 and 124 are mutated to Homocysteines that results in a disulfide bond with a cyclic structure.
  • the purified peptide was analyzed by LC/MS (Method A). [M+3H] 3+ mass signal found under the peak with retention time 3.57 min revealed the peptide mass 1195.4 which is in line with the expected value of molecular weight 3583.22.
  • Seq ID 8 (PepSP1071) spans the region Prol33-Lysl58 of CD31 IgL2-A.
  • Seq ID 9 spans the region Prol33-Lysl58 of CD31 IgL2-A as seq ID 8 but with mutations homocysteines at position 35 and 52 that results in a disulfide bond with a cyclic structure.
  • the resin was treated with Ac2O (10 eq) in DMF for 30 mins.
  • Crude material was dissolved in a 9/1 mixture of DMSO/H2O at 1 mg/mL concentration: aqueous NH3 added to reach pH 9 and the mixture was stirred for 72 hours at room temperature. After this time the formation of the disulfide bridge was confirmed by UPLC, TFA added to quench the reaction mixture and then it was freeze dried.
  • the purified peptide was analyzed by LC/MS (Method B). [M+4H] 4+ mass signal found under the peak with retention time 3.23 min revealed the peptide mass 1076.8 which is in line with the expected value of 4301.09 molecular weight.
  • Seq ID 10 is the heterodimer obtained through a thioether linkage between hCys8 of intermediate A (INT A) (QHQMLFYhC#DDVLFYNISSMK-CONH2) and the bromoacetyl group of intermediate B (INT B) [BrCH 2 CO- G#TYKSTVIVNNKEKTTAEYQ-(Ttds)4-K(N3)-NH 2 ].
  • Seq ID 11 is the heterodimer obtained through a thioether linkage between hCys8 of intermediate A (INTA (QHQMLFYhCDDVLFYNISSMK-CONH 2 ) and the bromoacetyl group of intermediate C (INT C) [Ac-K(N 3 )-(Ttds) 4 - PRVTLDKKEAIQGGIVRVNSSVPEEK-Ttds-K(BrCH 2 CO)-CONH 2 ].
  • the linear precursor common intermediate for heterodimers Seq ID 10 and 11 was prepared following the general procedure for the synthesis and cleavage: all the Fmoc deprotections were performed at room temperature.
  • the crude peptide was purified using Reprosil C4 (250x40mm, 120 A, 5 pm) as column and the following gradient of eluent B: 20% B for 5 min; 20% of B to 40% in 25 min; flow rate: flow rate 60 mL/min, wavelength 214 nm.
  • Linear precursor for heterodimer Seq ID 10 was prepared following the general procedure for the synthesis.
  • the free amino group on the last residue on the resin (gly) was treated with bromoacetic acid (5 eq) according to the DIC/HOAt method (4 equivalent excess with respect to resin loading) in DMF.
  • the mixture was shaken at room temperature for 1 h and the reaction was monitored by Kaiser Test.
  • the resin was filtered and washed with DMF/DCM/DMF (6/6/6 time each) and treated with the cleavage mixture (Mix 1) as reported in the general synthetic procedure.
  • the crude peptide was purified by RP-HPLC using Reprosil C4 (250x40mm, 120 , 5pm) column and the following gradient: 20% B for 5 min; 20% of B to 40% in 25 min; flow rate: flow rate 60 mL/min, wavelength 214 nm.
  • Linear precursor C for heterodimer Seq ID 11 was prepared following the general synthetic procedure.
  • the first amino acid loaded onto the resin was Lys protected with alloc on the side chain amino group.
  • Double acylations were performed on the following residues: SVP, IVRV and PRVTL: after the PRVTL residues all Fmoc deprotections were performed at room temperature.
  • the resin was filtered and washed with DMF/DCM/DMF (6/6/6 time each) and treated with the cleavage mixture (Mix 1) as reported in the general synthetic procedure.
  • the crude peptide was purified: Reprosil C4 (250x40mm, 120A, 5pm) column and the following gradient: 20% B for 5 min; 20% of B to 40% in 25 min; flow rate: flow rate 60 mE/min, wavelength 214 nm.
  • Nitinol disks are left untouched (bare metal) or coated with a domain 1, domain 2 or domain 1 and 2 CD31 analog peptide.
  • the tested peptide is grafted to the nitinol disk following a polydopamine, DBCO-PEG4-amine and azide CD31 derivative peptide using a sequential dip-coating layering procedure. After this step, all the disks are incubated with Human aortic endothelial cells for 48h. Disks are then rinsed and the cells are fixed in a formalin solution before staining.
  • the staining is fulfilled using phalloidin coupled to AlexaFluor®488 dye (green fluorescence for Actin), DAPI is used for DNA staining and a domain 1 CD31 antibody coupled to APC is used for external Domain 1 staining.
  • phalloidin coupled to AlexaFluor®488 dye (green fluorescence for Actin)
  • DAPI used for DNA staining
  • a domain 1 CD31 antibody coupled to APC is used for external Domain 1 staining.
  • the cell adhesion and Actin/CD31 expression was evaluated by image analysis of the surface after staining.
  • HAEC Primary Human Aortic Endothelial Cells
  • Disk- adherent cells were immersed in a solution comprising Hoechst 33342 (1 pg/ml, to stain the nuclei), phalloidin coupled to AlexaFluor®488 dye (0,5uM, to stain F-actin fibers) and a monoclonal antibody directed against CD31 domain 1 , coupled to allophycocyanin (to detect the presence and localization of intact CD31 at the cell surface) for 1 hour at 37°C, washed and mounted face down on glass bottom imaging chambers for imaging with an inverted fluorescence microscope. Representative images show that HAEC growing on bare material displayed a strong F-actin staining, reflecting enhanced formation of stress fibers whereas the expression of intact CD31 was rather faint. At the opposite, disks coated with CD31 -mimetic peptides displayed little stress fibers signal and an intense and uniform CD31 expression at the cell borders, reflecting a more physiologic endothelial phenotype.
  • the F-actin expression relates the cellular stress of the cell in presence of the exogenous material. All surface modification lead to a decrease in cellular stress compared to the bare metal, except for the 1070 peptide, which does not show an influence on the cellular stress compared to the bare metal.
  • CD31 expression relates the capacity of endothelial cells to adopt a physiologic phenotype while growing on a given substrate. An important variability is observed in terms of CD31 expression by HAEC according to the surface modification of the nitinol disks. Four of the displayed CD31 analog peptide (peptide 1072-1374-1375 and 1380) exert an evident positive effect in terms of CD31 expression as compared to the other modified disks and bare controls.
  • the “mirror” bars of Figure 5 report the average Integrated Density of F-actin (left) and of CD31 (right) staining for each of the indicated (Y axis) type of peptide coated onto the disk surface and bare disks. Data are sorted (from the top to the bottom) according to the increase in the cellular stress (actin expression) of each coating. As shown on the figure, the degree of cellular stress (as detected by a high actin expression) and impaired endothelial phenotype (documented by a low CD31 expression) is evident on HAEC grown onto bare metal disks. On the contrary, the CD31 -mimetic surfaces, such the disks coated with the 1374 peptide, lead to a low cellular stress (low actin expression) and consistent functional endothelial phenotype (high CD31 expression).
  • the coating of the device or of device-suitable components is achieved through a three-step dip-coating during which the sample is allowed to be completely coated by dynamic dipping.
  • the first bath is composed of Polydopamine (2 mg/ml in tris buffer, pH 8.5) over a period of 22 ⁇ 2 hours.
  • the second bath allows the grafting of the click-chemistry-suitable linker (for instance DBCO-PEG 4 -Amine, 300 iiM).
  • the third bath consists in a solution of the chosen Azide-derivatized CD31 analog peptide (domain 1-2 or 1 and 2).
  • the P8RI sequence can uphold the clusterisation of truncated CD31 molecules expressed by activating cells
  • the presence of the invention peptides allows the engagement of intact CD31 molecules on all the healthy endothelial cells and resting blood platelets and leukocytes that can enter in contact with an implanted device.
  • Those cells can therefore receive the “leave-me-alone” signal delivered by the trans-homophilic engagement of CD31 , which is essential to maintain the homeostasis in the circulation and vascularized tissues.
  • the devices bearing the mimicking peptides of the present invention are rapidly integrated, because they are perceived by blood platelets and leukocytes as a healthy endothelium, a “self’ component. Furthermore, their ability to be rapidly endothelialized with a physiologic endothelial cell phenotype also limits platelet and leukocyte activation at the site of device implantation in the long-term.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Prostheses (AREA)
PCT/IB2021/000860 2021-12-03 2021-12-03 Cd31 mimetic coating for endovascular stent Ceased WO2023099932A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
PCT/IB2021/000860 WO2023099932A1 (en) 2021-12-03 2021-12-03 Cd31 mimetic coating for endovascular stent
JP2024532974A JP2024542778A (ja) 2021-12-03 2022-12-02 血管内ステント用の生体模倣コーティング
EP22829836.0A EP4440643A2 (en) 2021-12-03 2022-12-02 Medical device with cd31 mimetic coating
AU2022402537A AU2022402537B2 (en) 2021-12-03 2022-12-02 Medical device with cd31 mimetic coating
US18/715,588 US20250281679A1 (en) 2021-12-03 2022-12-02 Biomimetic coating for endovascular stent
KR1020247022306A KR20240155186A (ko) 2021-12-03 2022-12-02 혈관 내 스텐트용 생체모방 코팅
PCT/IB2022/000684 WO2023099957A2 (en) 2021-12-03 2022-12-02 Biomimetic coating for endovascular stent
CN202280082480.3A CN118843485A (zh) 2021-12-03 2022-12-02 血管内支架的仿生涂层
EP22830701.3A EP4440644A2 (en) 2021-12-03 2022-12-02 Cd31 mimetic coating for endovascular stent
CA3241253A CA3241253A1 (en) 2021-12-03 2022-12-02 Biomimetic coating for endovascular stent
KR1020247022289A KR20240155852A (ko) 2021-12-03 2022-12-02 혈관 내 스텐트용 생체모방 코팅
PCT/EP2022/084241 WO2023099748A2 (en) 2021-12-03 2022-12-02 Biomimetic coating for endovascular stent
CN202280082519.1A CN118475376A (zh) 2021-12-03 2022-12-02 具有cd31仿生涂层的医疗器械
US18/715,251 US20250381324A1 (en) 2021-12-03 2022-12-02 Cd31 mimetic coating for endovascular stent
JP2024532976A JP2024542779A (ja) 2021-12-03 2022-12-02 血管内ステント用の生体模倣コーティング
IL313268A IL313268A (en) 2021-12-03 2022-12-02 A medical device with a CD31 mimetic coating
MX2024006730A MX2024006730A (es) 2021-12-03 2024-05-31 Recubrimiento biomimetico para endoprotesis vascular

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/000860 WO2023099932A1 (en) 2021-12-03 2021-12-03 Cd31 mimetic coating for endovascular stent

Publications (1)

Publication Number Publication Date
WO2023099932A1 true WO2023099932A1 (en) 2023-06-08

Family

ID=79601491

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/IB2021/000860 Ceased WO2023099932A1 (en) 2021-12-03 2021-12-03 Cd31 mimetic coating for endovascular stent
PCT/EP2022/084241 Ceased WO2023099748A2 (en) 2021-12-03 2022-12-02 Biomimetic coating for endovascular stent
PCT/IB2022/000684 Ceased WO2023099957A2 (en) 2021-12-03 2022-12-02 Biomimetic coating for endovascular stent

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/EP2022/084241 Ceased WO2023099748A2 (en) 2021-12-03 2022-12-02 Biomimetic coating for endovascular stent
PCT/IB2022/000684 Ceased WO2023099957A2 (en) 2021-12-03 2022-12-02 Biomimetic coating for endovascular stent

Country Status (9)

Country Link
US (2) US20250381324A1 (cg-RX-API-DMAC7.html)
EP (2) EP4440643A2 (cg-RX-API-DMAC7.html)
JP (2) JP2024542779A (cg-RX-API-DMAC7.html)
KR (2) KR20240155186A (cg-RX-API-DMAC7.html)
CN (2) CN118843485A (cg-RX-API-DMAC7.html)
CA (1) CA3241253A1 (cg-RX-API-DMAC7.html)
IL (1) IL313268A (cg-RX-API-DMAC7.html)
MX (1) MX2024006730A (cg-RX-API-DMAC7.html)
WO (3) WO2023099932A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010000741A1 (en) * 2008-06-30 2010-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders
WO2020109833A1 (en) * 2018-11-27 2020-06-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for the modification of a substrate surface by grafting a peptide onto the surface of said substrate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2294321A (en) * 1994-10-19 1996-04-24 Yamanouchi Research Inst Method of screening for CD31 interaction inhibitors
WO2013190014A1 (en) * 2012-06-19 2013-12-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Improved cd31 peptides
WO2018191681A1 (en) 2017-04-13 2018-10-18 Orbusneich Medical, Inc. Medical devices coated with polydopamine and antibodies
EP3886933A1 (en) 2018-11-27 2021-10-06 Balt Extrusion Method for the modification of a device surface by grafting a cd31-derived peptide onto the surface of said device
US20230241057A1 (en) 2020-05-28 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Compounds for the prevention, treatment and diagnosis of thrombi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010000741A1 (en) * 2008-06-30 2010-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders
WO2020109833A1 (en) * 2018-11-27 2020-06-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for the modification of a substrate surface by grafting a peptide onto the surface of said substrate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIAZ-RODRIGUEZ SERGIO ET AL: "Coronary stent CD31-mimetic coating favours endothelialization and reduces local inflammation and neointimal development in vivo.", EUROPEAN HEART JOURNAL 07 05 2021, vol. 42, no. 18, 7 May 2021 (2021-05-07), pages 1760 - 1769, XP055945712, ISSN: 1522-9645 *
QUOCTHANG HOANG ET AL: "Peptide binding to cleaved CD31 dampens ischemia/reperfusion-induced intestinal injury", INTENSIVE CARE MEDICINE EXPERIMENTAL, BIOMED CENTRAL LTD, LONDON, UK, vol. 6, no. 1, 15 August 2018 (2018-08-15), pages 1 - 12, XP021259664, DOI: 10.1186/S40635-018-0192-3 *
WERNER HELD ET AL: "Cis-trans interactions of cell surface receptors: biological roles and structural basis", CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHÄUSER-VERLAG, BA, vol. 68, no. 21, 24 August 2011 (2011-08-24), pages 3469 - 3478, XP019964063, ISSN: 1420-9071, DOI: 10.1007/S00018-011-0798-Z *

Also Published As

Publication number Publication date
KR20240155186A (ko) 2024-10-28
EP4440643A2 (en) 2024-10-09
AU2022402537A1 (en) 2024-07-11
CN118475376A (zh) 2024-08-09
US20250281679A1 (en) 2025-09-11
US20250381324A1 (en) 2025-12-18
CN118843485A (zh) 2024-10-25
JP2024542779A (ja) 2024-11-15
IL313268A (en) 2024-08-01
JP2024542778A (ja) 2024-11-15
KR20240155852A (ko) 2024-10-29
CA3241253A1 (en) 2023-06-08
WO2023099748A2 (en) 2023-06-08
WO2023099748A3 (en) 2023-07-13
WO2023099957A3 (en) 2023-07-13
MX2024006730A (es) 2024-11-08
EP4440644A2 (en) 2024-10-09
WO2023099957A2 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
EP0730607B1 (en) Novel integrin-binding peptides
US4935492A (en) Cyclic analogs of atrial natriuretic peptides
AU2007200030B2 (en) Reagents and methods for smooth muscle therapies
US5434133A (en) CNP analog peptides and their use
JPH03500046A (ja) フィブロネクチン活性を有するポリペプチド
KR101417872B1 (ko) 59번 위치에 아미노산 치환을 포함하는 인슐린 유사 성장 인자-1(igf-1)의 유사체
JP2819467B2 (ja) 新規なカルジオジラチン断片およびその製造方法
JPH09505555A (ja) TGF−βの活性を刺激および阻害する方法および組成物
WO2020109833A1 (en) Method for the modification of a substrate surface by grafting a peptide onto the surface of said substrate
US8227411B2 (en) FGF growth factor analogs
EP3886933A1 (en) Method for the modification of a device surface by grafting a cd31-derived peptide onto the surface of said device
US20040054143A1 (en) Vegf peptides and their use for inhibiting angiogenesis
AU2002210713A1 (en) VEGF peptides and their use for inhibiting angiogenesis
US20250381324A1 (en) Cd31 mimetic coating for endovascular stent
KR101934047B1 (ko) 티타늄 결합능을 가지는 펩타이드
KR101681886B1 (ko) 지르코니아 결합능을 가지는 펩타이드
JP4104671B2 (ja) 潜在型TGF―βの活性化を促進するペプチドおよびTGF―β活性調節化合物のスクリーニング方法
US6872803B1 (en) Peptides
Anderson Extracellular matrix biomimicry for the endothelialization of cardiovascular materials
WO1996019501A1 (en) Modulators of bone cell function and uses thereof
CN113366013A (zh) 新型化合物和包含其的血管生成剂
JPH08143593A (ja) 新規ペプチド及びその塩

Legal Events

Date Code Title Description
WA Withdrawal of international application
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21843766

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21843766

Country of ref document: EP

Kind code of ref document: A1